Atricure Stock Price, News & Analysis

AtriCure (Nasdaq: ATRC) reported Q3 2025 results: revenue $134.3M (+15.8% YoY; +15.1% constant currency), gross profit $101.3M and gross margin 75.5% (up 59 bps). Q3 net loss was $0.3M (basic/diluted loss $0.01), an improvement of $7.6M versus prior year. Adjusted EBITDA $17.8M (up $9.9M YoY). The company generated $30.1M cash in Q3 and reported cash and equivalents of $147.9M at Sept 30, 2025. Management raised full‑year 2025 guidance to $532M–$534M revenue, Adjusted EBITDA of $55M–$57M, and adjusted loss per share of $0.23–$0.26. A conference call was scheduled for Oct 29, 2025 at 4:30 PM ET.

AtriCure (Nasdaq: ATRC) announced the first patient was enrolled and treated in the BoxX-NoAF randomized IDE clinical trial on October 28, 2025. The trial will evaluate the safety and effectiveness of the Isolator Synergy EnCompass clamp combined with the AtriClip Left Atrial Appendage Exclusion System to reduce new-onset or post-operative atrial fibrillation (POAF) in cardiac surgery patients.

BoxX-NoAF is a prospective, multicenter, randomized trial of up to 960 subjects at up to 75 sites worldwide. AtriCure cited prior enrollment completion of the LeAAPS trial in July 2025 and framed BoxX-NoAF as intended to inform practice and potential labeling for concomitant surgical ablation with LAA management.

AtriCure (Nasdaq: ATRC) announced management will participate in two investor fireside discussions in November 2025. Presentations are scheduled at the UBS Global Healthcare Conference on Monday, November 10, 2025 at 2:00 PM ET and the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 8:40 AM ET.

Both sessions will be available via live audio webcast accessible from the company’s Investors website at https://ir.atricure.com. The presentations will cover the company’s developments in atrial fibrillation treatment, left atrial appendage management, and post-operative pain management.

AtriCure (Nasdaq: ATRC) will release its third quarter 2025 financial results on Wednesday, October 29, 2025. The company will host an audio webcast at 4:30 p.m. Eastern Time the same day to discuss results; interested participants are asked to register online and to register more than 15 minutes before the call. A live and replay version of the audio webcast will be available via the company's investor events page at https://ir.atricure.com/events-and-presentations/events.

AtriCure (NASDAQ: ATRC) has launched the cryoXT™ device, a new cryoablation technology designed for post-operative pain management following amputation procedures. The device, recently cleared by the FDA under a 510(k), addresses a significant market need with over 185,000 annual amputations in the U.S., where approximately 60% of patients experience residual limb pain and up to 85% report phantom limb pain.

The cryoXT device builds upon AtriCure's successful cryoICE® platform, which has been used in over 100,000 procedures since November 2018. The technology features a newly designed tip with multi-surface freezing capability to target large diameter exposed peripheral nerves, temporarily blocking post-amputation pain through nerve ablation.

AtriCure (NASDAQ:ATRC), a leader in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the 2025 Wells Fargo Healthcare Conference.

The company's management will engage in a fireside chat on September 3, 2025, at 3:45 p.m. EST. Investors and interested parties can access the live audio webcast through AtriCure's investor relations website at ir.atricure.com.

AtriCure (NASDAQ:ATRC), a leader in surgical treatments for atrial fibrillation, reported strong Q2 2025 financial results and raised its outlook. The company achieved revenue of $136.1 million, up 17.1% year-over-year, with U.S. revenue at $110.6 million (+15.7%) and international revenue at $25.6 million (+23.3%).

Key highlights include a net loss improvement to $6.2 million from $8.0 million year-over-year, and Adjusted EBITDA of $15.4 million, increasing by $7.6 million. The company generated $17.9 million in cash during the quarter and completed enrollment of 6,500 patients in the LeAAPS trial.

AtriCure raised its 2025 guidance, now projecting full-year revenue of $527-533 million and Adjusted EBITDA of $49-52 million. The company expects modest cash flow generation for 2025.

AtriCure (NASDAQ:ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference.

The company's management team will deliver their presentation on Tuesday, August 12, 2025, at 2:30 p.m. EST. Investors and interested parties can access the live audio webcast through the Investors section of AtriCure's website.

AtriCure (NASDAQ: ATRC) has completed enrollment in its landmark LeAAPS clinical trial, the largest cardiac surgery device trial ever conducted with 6,500 patients across 137 centers globally. The trial evaluates the AtriClip® LAA Exclusion System for stroke prevention in cardiac surgery patients without pre-existing atrial fibrillation.

The study targets a significant market opportunity, as over one million cardiac surgery procedures occur annually, with more than 70% of patients having no prior Afib history. The trial, initiated in January 2023, will continue with five years of follow-up to assess long-term outcomes. AtriCure aims to use the trial data to support an expanded indication for stroke prevention in high-risk patients.